ArticleScientific reports2018
Nano-particle mediated inhibition of Parkinson's disease using computational biology approach.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Periodic Table of Immunomodulatory Elements and Derived Two-Dimensional Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives.Frontiers in medicine · 2025Review
- Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review.Discover nano · 2023Review
- Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform.Molecules (Basel, Switzerland) · 2023Review
- Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders.Nanomaterials (Basel, Switzerland) · 2022Review
- Cationic Carbosilane Dendrimers Prevent Abnormal α-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons.Biomacromolecules · 2021Article
- Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders.Nanomaterials (Basel, Switzerland) · 2021Review
- Interaction of silver nanoparticles with catecholBiochemistry and biophysics reports · 2021Article
- Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Personalized Healthcare for Dementia.Healthcare (Basel, Switzerland) · 2021Review
- Emerging Nanotechnology for Treatment of Alzheimer's and Parkinson's Disease.Frontiers in bioengineering and biotechnology · 2021Review
- Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases.Biomaterials science · 2020Article
- Luminescent chitosan/carbon dots as an effective nano-drug carrier for neurodegenerative diseases.RSC advances · 2020Article
- Cerium Oxide Nanoparticles Rescue α-Synuclein-Induced Toxicity in a Yeast Model of Parkinson's Disease.Nanomaterials (Basel, Switzerland) · 2020Article
- Homing of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) Labeled Adipose-Derived Stem Cells by Magnetic Attraction in a Rat Model of Parkinson's Disease.International journal of nanomedicine · 2020Article
- Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases.Frontiers in neuroscience · 2020Review
- Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease.Scientific reports · 2019Article
- Evaluation of caffeine as inhibitor against collagenase, elastase and tyrosinase using in silico and in vitro approach.Journal of enzyme inhibition and medicinal chemistry · 2019Article
- Evaluation of anti-EGFR-iRGD recombinant protein with GOLD nanoparticles: synergistic effect on antitumor efficiency using optimized deep neural networks.RSC advances · 2019Article
- Cerium oxide NPs mitigate the amyloid formation of α-synuclein and associated cytotoxicity.International journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) arises as neurodegenerative disorder and characterized by progressive deterioration of motor functions due to forfeiture of dopamine-releasing neurons. During PD, neurons at stake loss their functionality that results into cognition impairment and forgetfulness, commonly called as dementia. Recently, nanoparticles (NPs) have been reported for easy drug delivery through blood-brain barrier (BBB) into the central nervous system (CNS) against the conventional drug delivery systems. However, present study attempted to elucidate the α-synuclein activity, a major factor casing PD, in presence of its inhibitor cerium oxide (CeO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.